OralTox Oral Fluid Drug Test
Device Facts
| Record ID | K171403 |
|---|---|
| Device Name | OralTox Oral Fluid Drug Test |
| Applicant | Premier Biotech, Inc. |
| Product Code | DJC · Clinical Toxicology |
| Decision Date | Feb 2, 2018 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.3610 |
| Device Class | Class 2 |
Indications for Use
The OralTox™ Oral Fluid Drug Test is a competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Cocaine, Marijuana (THC), Methamphetamine, Opiates and Phencyclidine, in human oral fluid at the cutoff concentrations listed below and their metabolites: Test Calibrator Cutoff (ng/mL) Amphetamine (AMP) d-Amphetamine 50 Cocaine (COC) Benzoylecgonine 20 Marijuana (THC) Delta-9 -Tetrahydrocannabinol 40 Methamphetamine (MET) d-Methamphetamine 40 Opiates (OPI) Morphine 40 Phencyclidine (PCP) Phencyclidine 10 The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Liquid Chromatography/Mass Spectrometry, Mass Spectrometry (LC/MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only.
Device Story
OralTox Oral Fluid Drug Test is a lateral flow immunochromatographic assay for qualitative detection of six drug classes in human oral fluid. Device includes integrated collection swab, sponge, and saturation indicator strip; indicator turns red upon collection of adequate volume for testing and potential laboratory confirmation. Used at point-of-care; operated by healthcare professionals. Sample migrates via capillary action; competitive binding principle used where target drugs compete with drug-conjugates for monoclonal antibody binding sites. Absence of test line indicates presence of drug above cutoff; presence of control line validates test performance. Results are visually read. Preliminary positive results necessitate confirmatory testing via LC-MS/MS. Benefits include rapid, on-site screening to inform clinical decision-making.
Clinical Evidence
Method comparison study performed at three sites with 852 samples compared against LC-MS/MS. Results demonstrated high concordance across all analytes. Precision/reproducibility studies conducted using spiked samples at concentrations ranging from -100% to +100% of cutoff. Analytical specificity and cross-reactivity evaluated against numerous compounds; no significant interference observed. Sample volume and recovery studies confirmed adequacy of collection and stability for shipping to confirmation labs.
Technological Characteristics
Lateral flow immunochromatographic assay; competitive binding principle. Uses monoclonal mouse antibodies. Integrated collection tool with saturation indicator. Qualitative, visually read. No external energy source. Stable for 24 months at 4-30°C.
Indications for Use
Indicated for qualitative detection of Amphetamine, Cocaine, Marijuana (THC), Methamphetamine, Opiates, and Phencyclidine in human oral fluid. For prescription use only. Preliminary results require confirmation via LC/MS/MS.
Regulatory Classification
Identification
A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose.
Special Controls
*Classification.* Class II (special controls). A methamphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Predicate Devices
- The Oratect Oral Fluid Drug Screen Device (K103227)
Related Devices
- K181305 — OralTox Oral fluid Drug Test · Premier Biotech, Inc. · Sep 20, 2018
- K253705 — Healgen® Accurate Oral Fluid Drug Test · Healgen Scientific,, LLC · Mar 16, 2026
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
A. 510(k) Number:
k171403
B. Purpose for Submission:
New device
C. Measurands:
Amphetamine, cocaine, Marijuana, methamphetamine, morphine, and phencyclidine
D. Type of Test:
Qualitative, lateral flow immunochromatographic
E. Applicant:
Premiere Biotech, Incorporated
F. Proprietary and Established Names:
OralTox Oral Fluid Drug Test
G. Regulatory Information:
| Product Code | Classification | Relation Section | Panel |
| --- | --- | --- | --- |
| DKZ | Class II | 21CFR 862.3100, Amphetamine Test System | Toxicology (91) |
| DIO | Class II | 21 CFR 862.3250, Cocaine and metabolites Test System | Toxicology (91) |
| LDJ | Class II | 21 CFR 862.3870, Cannabinoids Test System | Toxicology (91) |
| DJC | Class II | 21 CFR 862.3610, Methamphetamine Test System | Toxicology (91) |
| LCM | Class II | Unclassified, Enzyme immunoassay Phencyclidine | Toxicology (91) |
| DJG | Class II | 21 CFR 862.3650, Opiate Test System | Toxicology (91) |
H. Intended Use:
1. Intended use(s):
{1}
Refer to Indications for Use below
2. Indication(s) for use:
The OralTox Oral Fluid Drug Test is a competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Cocaine, Marijuana (THC), Methamphetamine, Opiates and Phencyclidine, in human oral fluid at the cutoff concentrations listed below:
| Test | Calibrator | Cut-off level |
| --- | --- | --- |
| Amphetamine (AMP) | d-Amphetamine | 50 ng/mL |
| Cocaine (COC) | Benzoylecgonine | 20 ng/mL |
| Cannabinoids (THC) | Delta-9 Tetrahydrocannabinol | 40 ng/mL |
| Methamphetamine (MET) | d-Methamphetamine | 50 ng/mL |
| Morphine (MOP) | Morphine | 40 ng/mL |
| Phencyclidine (PCP) | Phencyclidine | 10 ng/mL |
The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Liquid Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.
For in vitro diagnostic use only.
3. Special conditions for use statement(s):
For prescription point-of-care use.
4. Special instrument requirements:
Not applicable, as the device is a visually-read single use device.
Device Description:
The OralTox Oral Fluid Drug Test is an immunochromatographic assay that uses a lateral flow system for the qualitative detection of Amphetamine, cocaine, cannabinoids, methamphetamine, morphine, phencyclidine (target analytes) in human oral fluid. The device has a built-in sample collection tool, including collection swab and sponge, as well as a saturation indicator strip. The saturation indicator strip turns red when a volume of oral fluid has been collected that is adequate for both the OralTox test and for confirmation testing at a laboratory if the result is a presumptive positive.
OralTox Oral Fluid Drug Tests tests are the first step in a two-step process. The second step is to send the sample for confirmatory laboratory testing using a more specific method (e.g., LC-MS/MS) if preliminary positive results are obtained.
J. Substantial Equivalence Information:
1. Predicate device name(s):
{2}
Oratect Oral Fluid Drug Screen Device
2. Predicate 510(k) number(s):
k103227
3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended Use | Same | Preliminary Drug screening test for the qualitative detection of drug analytes in oral fluid (human saliva) For In Vitro Diagnostic Use |
| Drug analytes detected | Same | D-Amphetamine
Cocaine
Delta-9-Tetrahydrocannabinol
D-Methamphetamine
Morphine
Phencyclidine |
| Methodology | Same | Competitive binding, lateral flow
immunochromatographic assays based on the principle of antigen antibody
immunochemistry |
| Type of Test | Same | Qualitative |
| Specimen Type | Same | Human Oral fluid |
| Cutoffs | Same | AMP 50 ng/mL
COC 20 ng/mL
THC 40 ng/mL
MET 50 ng/mL
MOP 40 ng/ML
PCP 10 ng/mL |
| Differences | | |
| Item | Device | Predicate |
| Configuration | Cups | Testing Pads |
K. Standard/Guidance Document Referenced (if applicable):
None referenced
L. Test Principle:
The OralTox Oral Fluid Drug Test is an immunochromatographic assay that uses a lateral
{3}
flow system for the qualitative detection of Amphetamine, cocaine, Marijuana, methamphetamine, morphine, and phencyclidine (target analytes) in human oral fluid. The tests are lateral flow chromatographic immunoassays, consisting of one test strip per analyte. During testing, an oral fluid specimen migrates up the test strip by capillary action. If target drugs present in the oral fluid specimen are below the cut-off concentration, it will not saturate the binding sites of its specific monoclonal mouse antibody coated on the particles. The antibody-coated particles will then be captured by immobilized drug-conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the target drug level exceeds its cutoff-concentration because it will saturate all the binding sites of the antibody coated on the particles. A band should form in the control region of the devices regardless of the presence of drug or metabolite in the sample to indicate that the tests have been performed properly.
## M. Performance Characteristics (if/when applicable):
### 1. Analytical performance:
#### a. Precision/Reproducibility:
Precision-Reproducibility-Cut-Off studies were carried out for samples with concentrations of -100% cut off, -75% cut off, -50% cut off, -25% cut off, cut off, +25% cut off, +50% cut off, +75% cut off and +100% cut off. These samples were prepared by spiking drug in negative oral fluid samples. The sponsor has stated that each drug concentration was confirmed by LC-MS/MS. All sample aliquots were blindly labeled by the person who prepared the samples and didn't take part in the sample testing. For each concentration, tests were performed two runs per day for 10 days per device lot in a randomized order. The sponsor provided the following summaries.
Amphetamine
| | -100% cut off | -75% cut off | -50% cut off | -25% cutoff | cut off | +25% cut off | +50% cut off | +75% cut off | +100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 53+/7- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 51+/9- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 56-/4+ | 49+/11- | 54+/6- | 60+/0- | 60+/0- | 60+/0- |
Cocaine
| | -100% cut off | -75% cut off | -50% cut off | -25% cutoff | cut off | +25% cut off | +50% cut off | +75% cut off | +100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 56-/4+ | 52+/8- | 54+/6- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 50+/10- | 54+/6- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 48+/12- | 56+/4- | 60+/0- | 60+/0- | 60+/0 |
Methamphetamine
| | -100% cut off | -75% cut off | -50% cut off | -25% cutoff | cut off | +25% cut off | +50% cut off | +75% cut off | +100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 50+/10- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 49+/11- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 48+/12- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
{4}
Morphine
| | -100% cut off | -75% cut off | -50% cut off | -25% cutoff | cut off | +25% cut off | +50% cut off | +75% cut off | +100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 48+/12- | 57+/3- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 48+/12- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 50+/10- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
Phencyclidine
| | -100% cut off | -75% cut off | -50% cut off | -25% cutoff | cut off | +25% cut off | +50% cut off | +75% cut off | +100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 48+/12- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 49+/11- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 48+/12 | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
Cannabinoids
| | -100% cut off | -75% cut off | -50% cut off | -25% cutoff | cut off | +25% cut off | +50% cut off | +75% cut off | +100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 50+/10- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 50+/10- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 49+/11- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
The device has been developed with the following cutoffs:
| Calibrator | Cut-off (ng/mL) |
| --- | --- |
| d-Methamphetamine | 50 |
| Cocaine | 20 |
| Morphine | 40 |
| d-Amphetamine | 50 |
| Phencyclidine | 10 |
| Delta-9-Tetrahydrocannabinol | 40 |
## Sample Volume:
A sample volume study was conducted to confirm the reproducibility of adequate sample volume collection by the device. Operators collected samples at two sites from a total 136 subjects (including drug users) following the device's instructions for use. Operators swept the inside of volunteer's mouth (cheek, gums, and tongue), and then held the swab in the subject's mouth until the color indicator within the collection device indicated that collection was complete.
The sponsor reported that all subjects evaluated were able to provide sufficient sample (so that the collection device's color indicator showed adequate collection) within the recommended seven minute collection timeframe. Mean volume collected was $2.5 \pm 0.2 \mathrm{~mL}$, and time required for collection was $3.7 \pm 1.7$ minutes. The maximum time required for collection was reported as seven minutes, and the minimum volume collected was $2.2 \mathrm{~mL}$.
{5}
b. Linearity/assay reportable range:
Not applicable. These devices are intended for qualitative use only.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Accelerated stability studies have been conducted for the device. Protocols and acceptance criteria were described and found to be acceptable. The manufacturer claims that when stored un-opened at 4-30 °C, the device is stable for 24 months. Real time studies have been conducted and are ongoing.
## Sample Recovery
### Sample volume recovery:
A sample volume recovery study was conducted to confirm that adequate sample volume could be extracted from the device for confirmatory testing after collection and shipping. Operators collected samples at two sites from a total 194 subjects (including drug users) following the device's instructions for use. Devices containing oral fluid samples were then sent to the confirmation laboratory using overnight shipping. The sponsor reported that the confirmation lab was able to extract sufficient sample volume for the confirmation testing of all six analytes for all samples collected.
### Analyte recovery:
To confirm that preliminary positive results can be adequately measured via confirmation testing after being subject to the temperature conditions required for shipping and storage, negative oral fluid samples in glass bottles were spiked with a single analyte/bottle to concentrations approximately -50% and +50% of the cutoff. Samples were spiked using known standards. Each drug concentration was confirmed by LC-MS/MS. The samples were transferred to OralTox devices using the collection sponges. For each of 3 storage conditions (-20°C, 20-25°C, and 40°C), 12 devices were used (4 devices from each of 3 lots). For each device, drug was measured by LC-MS/MS at time zero and the devices containing the specimens were stored under the specified condition. Drug in the devices stored at 20-25°C and 40°C was measured by LC-MS/MS at two (2) days, and drug in the devices stored at -20°C was measured by LC-MS/MS at 90 days.
The minimum and maximum recovery from 12 devices per lot per storage condition is shown below.
Room Temperature 20-25°C (two day storage)
| | MET +50 | MET -50 | COC +50 | COC -50 | MOR +50 | MOR -50 | AMP +50 | AMP -50 | PCP +50 | PCP -50 | THC +50 | THC -50 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Max | 100.1 | 100.0 | 100.5 | 97.8 | 100.3 | 102.0 | 100.3 | 99.7 | 98.4 | 99.8 | 99.0 | 100 |
| Min | 94.4 | 89.8 | 96.6 | 92.5 | 93.6 | 96.4 | 95.6 | 93.2 | 92.8 | 94.9 | 94.3 | 93.3 |
40 °C (two day storage)
{6}
7
| | MET +50 | MET -50 | COC +50 | COC -50 | MOR +50 | MOR -50 | AMP +50 | AMP -50 | PCP +50 | PCP -50 | THC +50 | THC -50 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Max | 105.4 | 100.4 | 99.3 | 100.0 | 100.6 | 100.0 | 99.6 | 98.6 | 97.4 | 96.3 | 100.5 | 98.3 |
| Min | 87.2 | 92.1 | 95.0 | 92.1 | 95.8 | 90.3 | 90.3 | 92.5 | 89.9 | 87.6 | 91.4 | 91.6 |
-20 °C (90 day storage)
| | MET +50 | MET -50 | COC +50 | COC -50 | MOR +50 | MOR -50 | AMP +50 | AMP -50 | PCP +50 | PCP -50 | THC +50 | THC -50 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Max | 100.0 | 102.2 | 100.3 | 98.1 | 102.1 | 100 | 100.4 | 103.9 | 100.1 | 99.4 | 100 | 102.9 |
| Min | 94.5 | 89.1 | 95.4 | 92.1 | 91.8 | 91.1 | 93.5 | 87.4 | 90.0 | 88.0 | 92.2 | 93.1 |
Results indicate that samples may be stored at room temperature for up to two days, elevated temperature for up to do days (40 °C), and for up to 90 days at –20 °C, prior to confirmatory testing.
Quality control: Control materials are not supplied with the devices; however, the labeling provides information on how to obtain quality control materials. The device also contains a color indicator which is connected to the collection swab and turns red once sufficient oral fluid has been collected from a subject.
d. Detection limit:
See Precision/Reproducibility section in M.1.a above.
e. Analytical specificity:
To test cross reactivity, drug metabolites and other components that may be present in oral fluid samples were tested using three lots of the OralTox device. The following is a summary of the cross-reactivity study.
| d-Methamphetamine (Cutoff=50 ng/mL) | Result Positive at (ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| D -Methamphetamine | 50 | 100% |
| L -Methamphetamine | 5000 | 1% |
| Methoxymethamphetamine | 50 | 100% |
| Ephedrine | 250 | 20% |
| Phenylephrine | 1250 | 4% |
| Procaine | 2500 | 2% |
| Methylephedrine | 500 | 10% |
| Methylenedioxyethylamphetamine (MDEA) | 500 | 10% |
| 3,4-methylenedioxy-methamphetamine (MDMA) | 100 | 50% |
| Amphetamine | 100000 | 0.05% |
| L-Amphetamine | Negative at 10000 | <0.5% |
| D-Amphetamine | 100000 | 0.05% |
| 3,4-methylenedioxyamphetamine | Negative at 50000 | <0.1% |
{7}
8
| Cocaine
(Cut-off=20ng/mL) | Result Positive at
(ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| Cocaine | 20 | 100% |
| Benzoylecgonine | 20 | 100% |
| Cocaethylene | 25 | 80% |
| Procaine | 20000 | 0.1% |
| Ecgonine | 50000 | 0.04% |
| Ecgonine methyl ester | 10000 | 0.2% |
| Norcocaine | Negative at 10000 | <0.2% |
| Morphine
(Cut-off=40 ng/mL) | Result
Positive at(ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| Morphine | 40 | 100% |
| Acetylmorphine | 100 | 40% |
| Codeine | 50 | 80% |
| Ethylmorphine | 100 | 40% |
| Heroin | 1250 | 40% |
| Dihydrocodone | 50 | 80% |
| Hydromorphone | 250 | 16% |
| Thebaine | Negative at 20000 | <0.2% |
| Norcodeine | 15000 | 0.3% |
| Morphine 6-β-glucuronide | 100 | 40% |
| Oxycodone | 25000 | 0.2% |
| Oxymorphone | 25000 | 0.2% |
| Nalorphine | 25000 | 0.2% |
| Hydrocodone | 100 | 40% |
| 6-Monoacetylmorphine | 100 | 40% |
| Morphine 3-β-glucuronide | 100 | 40% |
| d-Amphetamine
(Cut-off=50 ng/mL) | Result
Positive at (ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| D -Amphetamine | 50 | 100% |
| 1-Amphetamine | 4000 | 1.25% |
| D,L-Amphetamine | 50 | 100% |
| Methoxyamphetamine | 200 | 25% |
| D,L-Amphetamine | 10,000 | 0.5% |
| Methylenedioxyamphetamine(MDA) | 250 | 20% |
| Benzodioxolylbutanamine (BDB) | 10000 | 0.5 |
| 3-Hydroxy Tyramine | 5000 | 1% |
| d,l-p-Chloramphetamine | 300 | 17% |
| Phenethylamine | 300 | 17% |
| d,l-Phenylpropanolamine | Negative at 10000 | <0.5% |
| Phentermine | Negative at 10000 | <0.5% |
| Methylenedioxyethylamphetamine (MDEA) | Negative at 10000 | <0.5% |
| Methylenedioxy-methamphetamine | Negative at 10000 | <0.5% |
{8}
9
| (MDMA) | | |
| --- | --- | --- |
| d-Methamphetamine | Negative at 10000 | <0.5% |
| l-Methamphetamine | Negative at 10000 | <0.5% |
| Hydroxyamphetamine | Negative at 10000 | <0.5% |
| Dimethylamylamine (DMAA) | Negative at 10000 | <0.5% |
| Methylbenzodioxolylbutanamine (MBDB) | Negative at 10000 | <0.5% |
| para-Methoxymethamphetamine (PMMA) | Negative at 10000 | <0.5% |
| Phendimetrazine | Negative at 10000 | <0.5% |
| Phenmetrazine | Negative at 10000 | <0.5% |
| Ephedrine (d-, or l-, or d-l form) | Negative at 10000 | <0.05% |
| diphenhydramine | Negative at 10000 | <0.05% |
| d-Pseudoephedrine | Negative at 10000 | <0.05% |
| Fenfluramine | Negative at 10000 | <0.05% |
| Isoxsuprine | Negative at 10000 | <0.05% |
| l-Pseudoephedrine | Negative at 10000 | <0.05% |
| Mephentermine | Negative at 10000 | <0.05% |
| PCP
(Cutoff=10ng/mL) | Result
Positive at (ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| Phencyclidine | 10 | 100% |
| Hydrocodone | 2000 | 0.5% |
| Hydromorphone | 2000 | 0.5% |
| Nalorphine | 10,000 | 0.1% |
| Tenocyclidine (TCP) | 2000 | 0.5% |
| 1-(1-phenylcyclohexyl)morpholine(PCM) | 15 | 67% |
| 4-hydroxyphencyclidine | 10 | 100% |
| EDDP | Negative at 10000 | <0.1% |
| Ketamine | Negative at 10000 | <0.1% |
| Prazepam | Negative at 10000 | <0.1% |
| Amitriptyline | Negative at 100000 | <0.01% |
| Amitriptyline | Negative at 100000 | <0.01% |
| (+) Brompheniramine | Negative at 100000 | <0.01% |
| (+) Chlorphenamine | Negative at 100000 | <0.01% |
| desmethylvenlafaxine | Negative at 100000 | <0.01% |
| Chlorpromazine | Negative at 100000 | <0.01% |
| Clomipramine | Negative at 100000 | <0.01% |
| Cyclizine | Negative at 100000 | <0.01% |
| Cyclobenzaprine | Negative at 100000 | <0.01% |
| Dexbrompheniramine | Negative at 100000 | <0.01% |
| Dextromethorphan | Negative at 100000 | <0.01% |
| Diphenhydramine | Negative at 100000 | <0.01% |
| Doxepin | Negative at 100000 | <0.01% |
| Doxylamine | Negative at 100000 | <0.01% |
| Imipramine | Negative at 100000 | <0.01% |
| Thioridazine | Negative at 100000 | <0.01% |
{9}
10
| Venlafaxine | Negative at 100000 | <0.01% |
| --- | --- | --- |
| Delta-9-Tetrahydrocannabinol
(Cut-off=40 ng/mL) | Result
Positive at(ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| Delta-9-Tetrahydrocannabinol | 40 | 100% |
| 11-nor-Δ9-THC-9 COOH | 12 | 333% |
| Δ8-Tetrahydrocannabinol | 75 | 53% |
| 11-hydroxy-Δ9-THC | 300 | 13% |
| Cannabinol | 2000 | 2% |
| Cannabidol | 10,000 | 0.4% |
| 11-Nor-Δ9-THC-carboxy-glucuronide | 75 | 53% |
| (-)-11-nor-9-carboxy-Δ9-THC | 50 | 80% |
| 11-nor-Δ8-THC-9-COOH | 20 | 200% |
| 8-beta-11-dihydroxy-Δ9-THC | 300 | 13% |
| 8-beta-hydroxy-Δ9-THC | 200 | 20% |
| Exo-THC | 75 | 53% |
| I-11-Nor-Δ9-THC-9-Carboxylic Acyl-Glucuronide | 15 | 267% |
| Δ8-THC | 82.5 | 49% |
| Δ8-THC Carboxylic Acid | 20 | 200% |
| Δ9-THC Carboxylic Acid | 12 | 333% |
**Exogenous Interference:** Potential interference from structurally unrelated compounds were tested by spiking the potentially interfering compound at a concentration of 10 ug/mL into drug free oral fluid or fluid containing the target drug with concentrations of 50% below and 50% above cutoff level. The following compounds were found not to interfere with test results at a concentration of 10 ug/mL for all samples tested.
| Acetaminophen | Digoxin | Nicotinamide |
| --- | --- | --- |
| Acetylcodeine | Dihydrocodeine | Nicotine |
| Allobarbital | diltiazem HCl | Noscapine |
| Alprazolam | Diphenhydramine HCl | Omeprazole |
| Amobarbital | DL-Propranolol | Papaverine |
| Apomorphine | Doxylamine | Pentazocine |
| Atenolol | Ecgonine methylester | Phentermine |
| Atropine | Estradiol | Phenylpropanolamine |
| Baclofen | Estrone | Phenytoin |
| Benzocaine | Fluconazole | Pioglitazone HCl |
| Butabarbital | Furosemide | Prednisolone |
| Caffeine | Hexobarbital | Prednisone |
| Cannabidiol | Hydrochlorothiazide | Procainamide HCl |
{10}
| Carbamazepine | Ibuprofen | Procaine HCL |
| --- | --- | --- |
| Chlordiazepoxide | Imipramine | Promethazine |
| Chlorpromazine | Lamotrigine | Quinine HCl |
| Cimetidine | Levetiracetam | R,R(-)-Pseudoephedrine |
| Citalopram HBr | Lidocaine | Salicylic Acid |
| Clobazam | Lormetazepam | Sertraline HCL |
| Clomipramine | L-Thyroxine | Simvastin |
| Clonazepam | Metformin HCl | Theophylline |
| Clonidine | Methylphenidate HCl | Thiamine |
| Clopidogrel bisulfate | Metoprolol | Topiramate |
| Cortisol | Metronidazole | Valproic Acid |
| Cotinine | Montelukast sodium salt | Verapamil |
| d,l-Salbutamol | Naloxone | Zonisamide |
| Deoxycorticosterone | Naltrexone | |
| Dextromethorphan | Naproxen | |
The following potential interference from substances commonly present in oral fluid were evaluated by spiking into drug free oral fluid or oral fluid containing the target drug with concentrations of 50% below and 50% above cutoff level to a concentration of 5%: alcohol, baking soda, chewing gum, coffee, cola, cough syrup, cranberry juice, food coloring (blue, green, and red), methanol cough drops, milk, mouthwash, MSG, orange juice, salt, sugar, tea, toothpaste, and tomatoes. None of these substances showed any interference with the detection of any analyte (MET, COC, MOP, AMP, PCP, THC) using the device.
Potential interference from cigarette smoking, was evaluated by asking a participant to smoke a cigarette, after 15 minutes and oral fluid sample was collected and spiked with each drug at concentrations of cutoff +/- 50%. No interference with the detection of any analyte (MET, COC, MOP, AMP, PCP, THC) using the device was observed.
Potential interference from Hemoglobin was evaluated by adding it to drug free oral fluid or oral fluid containing the target drug with concentrations of 50% above and 50% below cutoff level to a concentration of 100ug/mL. No interference with the detection of any analyte (MET, COC, MOP, AMP, PCP, THC) using the device was observed.
**Effect of oral fluid pH:** To investigate the effect of oral fluid pH, oral fluid samples with pH 4 to 9 were spiked with target drugs at 50% below and 50% above Cut-Off levels. These samples were tested using three lots of the device. Results were all positive for samples at and above +50% Cut-Off and all negative for samples at and below -50% Cut-Off.
There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results, e.g., technical or procedural errors.
f. Assay cut-off:
{11}
Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, M.1.a., above.
# 2. Comparison studies:
# a. Method comparison:
Method comparison studies for the OralTox Oral fluid Drug Test were performed at three testing sites with three operators at each site. Operators tested a total of 852 samples and compared to LC-MS/MS results. The results are presented in the tables below:
Methamphetamine
| Concentration Range (by LC-MS/MS) | Number of samples | Test Results | | percentage correct (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug-Free | 324 | 0 | 324 | 100 |
| Less than Half the Cutoff Concentration | 50 | 0 | 50 | 100 |
| Near Cutoff Negative (-50% to the cutoff concentration) | 15 | 2 | 13 | 87 |
| Near Cutoff Positive (cutoff to 50%) | 16 | 15 | 1 | 94 |
| High Positive (>50% cutoff) | 116 | 116 | 0 | 100 |
Discordant Results (Methamphetamine)
| LC-MS/MS Result | Device Results |
| --- | --- |
| 49.4 | Positive |
| 48.9 | Positive |
| 55.0 | Negative |
Cocaine
| Concentration Range (by LC-MS/MS) | Number of samples | Test Results | | percentage correct (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug-Free | 390 | 0 | 390 | 100 |
| Less than Half the Cutoff Concentration | 21 | 0 | 21 | 100 |
| Near Cutoff Negative (-50% to the cutoff concentration) | 19 | 1 | 18 | 95 |
| Near Cutoff Positive (cutoff to 50%) | 15 | 14 | 1 | 93 |
| High Positive (>50% cutoff) | 77 | 77 | 0 | 100 |
Discordant Cocaine Results:
| LC-MS/MS Result | Device Results |
| --- | --- |
| 17.0 | Positive |
| 22.7 | Negative |
{12}
Morphine:
| Concentration Range (by LC-MS/MS) | Number of samples | Test Results | | percentage correct (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug-Free | 323 | 0 | 323 | 100 |
| Less than Half the Cutoff Concentration | 50 | 0 | 50 | 100 |
| Near Cutoff Negative (-50% to the cutoff concentration) | 16 | 2 | 14 | 88 |
| Near Cutoff Positive (cutoff to 50%) | 19 | 18 | 1 | 95 |
| High Positive (>50% cutoff) | 114 | 114 | 0 | 100 |
Discordant Results for Morphine:
| LC-MS/MS Result | Device Results |
| --- | --- |
| 35.4 | Positive |
| 37.1 | Positive |
| 42.4 | Negative |
Amphetamine:
| Concentration Range (by LC-MS/MS) | Number of samples | Test Results | | percentage correct (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug-Free | 229 | 0 | 229 | 100 |
| Less than Half the Cutoff Concentration | 92 | 0 | 92 | 100 |
| Near Cutoff Negative (-50% to the cutoff concentration) | 61 | 2 | 59 | 97 |
| Near Cutoff Positive (cutoff to 50%) | 39 | 36 | 3 | 92 |
| High Positive (>50% cutoff) | 54 | 54 | 0 | 100 |
Discordant Results of Amphetamine:
| LC-MS/MS Result | Device Results |
| --- | --- |
| 48.3 | Positive |
| 49.5 | Positive |
| 53.2 | Negative |
| 52.1 | Negative |
| 53.5 | Negative |
{13}
14
Phencyclidine
| Concentration Range (by LC-MS/MS) | Number of samples | Test Results | | percentage correct (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug-Free | 407 | 0 | 407 | 100 |
| Less than Half the Cutoff Concentration | 20 | 0 | 20 | 100 |
| Near Cutoff Negative (-50% to the cutoff concentration) | 8 | 2 | 6 | 75 |
| Near Cutoff Positive (cutoff to 50%) | 4 | 4 | 0 | 100 |
| High Positive (>50% cutoff) | 38 | 38 | 0 | 100 |
Discordant Results for Phencyclidine:
| LC-MS/MS Result | Test Results |
| --- | --- |
| 9.75 | Positive |
| 9.89 | Positive |
Marijuana (THC)
| Concentration Range (by LC-MS/MS) | Number of samples | Test Results | | percentage correct (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug-Free | 359 | 0 | 359 | 100 |
| Less than Half the Cutoff Concentration | 27 | 0 | 27 | 100 |
| Near Cutoff Negative (-50% to the cutoff concentration) | 7 | 0 | 7 | 100 |
| Near Cutoff Positive (cutoff to 50%) | 9 | 6 | 3 | 67 |
| High Positive (>50% cutoff) | 54 | 54 | 0 | 100 |
Discordant Results for Marijuana (THC):
| LC-MS/MS Result | Test Results |
| --- | --- |
| 45.6 | Negative |
| 41.2 | Negative |
| 48.0 | Negative |
b. Matrix comparison:
Not applicable. These devices are for use with oral fluid samples only.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
{14}
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
15
